1. At a Glance — A Microcap That Suddenly started bullshitting

Some companies compound quietly. Some implode loudly. And then there are companies like AVI Polymers Ltd, which spend years looking dormant and then suddenly report ₹312 crore revenue, ₹20.3 crore PAT, 33.4% ROE, 45.5% ROCE, and trade at 8.39 times earnings.

That combination usually does not sit in microcaps for long without attracting attention.

But this is where it gets interesting.

For nearly a decade, the business looked tiny, almost irrelevant from a scale perspective. Then FY26 lands and revenue explodes from effectively negligible levels to ₹312 crore. Profit jumps. Margins appear. Working capital improves sharply. Debt is nearly absent. Then management raises ₹89.99 crore in rights capital and simultaneously launches an AI agritech subsidiary, KrishiBuddy.

Now pause.

Chemical trading company.

Turns profitable.

Launches AI agritech platform.

Rights issue of almost half its market cap.

Promoter ownership collapses to 1.1%.

Auditor changed.

CMD changed.

CFO changed.

Open offer happened.

If this doesn’t make you lean forward, what will?

This is where detective work starts.

Is this:

• A genuine re-rating candidate ignored by markets?
• A low-float speculative frenzy wearing growth clothing?
• Or one of those bizarre Indian microcap stories where everything looks impossible until suddenly it isn’t?

The valuation screams cheap.

Governance signals scream “look carefully.”

That tension is the entire story.

And that is what makes this fascinating.

Would you pay 8x earnings for a business growing this fast — if you trusted the earnings?

That “if” is doing heavy lifting.

2. Introduction — From Obscurity to Sudden Financial Shock

AVI Polymers did something markets rarely ignore.

It produced numbers too large relative to its size.

Market cap: ₹170 crore
Sales: ₹312 crore
PAT: ₹20 crore

Price-to-sales below 1.

EV/EBITDA 5.55.

That looks more like distressed pricing than growth pricing.

Yet this isn’t a textbook value case.

Because FY26 almost looks discontinuous versus history.

For years, operations were tiny.

Then suddenly:

• Q3 FY26 sales: ₹132 crore
• Q4 FY26 sales: ₹150 crore
• FY26 full-year sales: ₹312 crore

That is not growth.

That is resurrection.

Management attributes this to resumption of specialty chemicals trading activity and working capital deployment, helped by rights issue capital.

Possible.

But sudden transformations demand skepticism.

Markets often underprice turnarounds.

They also often overprice stories.

Which one is this?

Interesting clue:

Operating margins only 8.7%.

This is not some fantasy software valuation hiding behind margins.

This looks like ordinary trading economics.

Which oddly makes it more believable.

Yet the promoter holding at 1.1% is extraordinary.

That alone forces caution.

Would you trust a microcap where promoters own less than many retail investors?

That question matters.

3. Business Model — What Do They Even Do?

Strip away the AI glitter for a second.

This is primarily a trading business.

It buys and sells:

• Specialty chemicals
• Polymer compounds
• Dye intermediates
• Water treatment chemicals
• Detergent chemicals

Think margins from distribution and trading spreads, not patented chemistry.

Not glamorous.

Sometimes profitable.